Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Research & Development (2016 - 2025)

Palisade Bio has reported Research & Development over the past 16 years, most recently at $6.2 million for Q4 2025.

  • Quarterly Research & Development rose 196.21% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Dec 2025, down 55.54% year-over-year, with the annual reading at $10.2 million for FY2025, 12.46% up from the prior year.
  • Research & Development was $6.2 million for Q4 2025 at Palisade Bio, up from $1.4 million in the prior quarter.
  • Over five years, Research & Development peaked at $16.0 million in Q3 2024 and troughed at $314000.0 in Q2 2021.
  • The 5-year median for Research & Development is $1.7 million (2025), against an average of $2.5 million.
  • Year-over-year, Research & Development soared 660.46% in 2024 and then crashed 91.29% in 2025.
  • A 5-year view of Research & Development shows it stood at $624000.0 in 2021, then soared by 275.48% to $2.3 million in 2022, then crashed by 84.55% to $362000.0 in 2023, then surged by 475.69% to $2.1 million in 2024, then skyrocketed by 196.21% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Research & Development are $6.2 million (Q4 2025), $1.4 million (Q3 2025), and $1.7 million (Q2 2025).